Page 1675 - Williams Hematology ( PDFDrive )

1650 Part XI: Malignant Lymphoid Diseases Chapter 99: Follicular Lymphoma 1651

100% 16. Federico M, Bellei M, Marcheselli L, et al: Follicular lymphoma international prognos-
tic index 2: A new prognostic index for follicular lymphoma developed by the interna-
1995–Present tional follicular lymphoma prognostic factor project. J Clin Oncol 27:4555–4562, 2009.
80% 17. Press OW, Unger JM, Rimsza LM, et al: Phase III randomized intergroup trial of CHOP
plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab
1980s
60% for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol
31:314–320, 2013.
18. Press OW, Unger JM, Rimsza LM, et al: A comparative analysis of prognostic factor
1970s
40% models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus
4-Year CHOP + 131iodine-tositumomab. Clin Cancer Res 19:6624–6632, 2013.
N Deaths estimate 19. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on
20% 1995–Present 179 18 91% molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159–2169, 2004.
1980s 425 189 79% 20. Morin RD, Mendez-Lago M, Mungall AJ, et al: Frequent mutation of histone-modify-
1970s 356 226 69% ing genes in non-Hodgkin lymphoma. Nature 476:298–303, 2011.
0% 21. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al: Inactivating mutations of acetyl-
0 2 4 6 8 10 transferase genes in B-cell lymphoma. Nature 471:189–195, 2011.
Years after registration 22. Okosun J, Bodor C, Wang J, et al: Integrated genomic analysis identifies recurrent
mutations and evolution patterns driving the initiation and progression of follicular
lymphoma. Nat Genet 46:176–181, 2014.
Figure 99–7. Improved survival of patients with follicular lymphoma 23. Green MR, Gentles AJ, Nair RV, et al: Hierarchy in somatic mutations arising during
treated by the Southwest Oncology Group. (Reproduced with permis- genomic evolution and progression of follicular lymphoma. Blood 121:1604–1611,
sion from Fisher RI, LeBlanc M, Press OW, et al: New treatment options have 2013.
changed the survival of patients with follicular lymphoma. J Clin Oncol 24. Bodor C, Grossmann V, Popov N, et al: EZH2 mutations are frequent and represent an
23(33):8447–8452, 2005.) early event in follicular lymphoma. Blood 122:3165–3168, 2013.
25. Advani R, Rosenberg SA, Horning SJ: Stage I and II follicular non-Hodgkin’s lym-
phoma: Long-term follow-up of no initial therapy. J Clin Oncol 22:1454–1459, 2004.
26. Schmatz AI, Streubel B, Kretschmer-Chott E, et al: Primary follicular lymphoma of the
attributable to the introduction of rituximab, better salvage therapies duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: A retro-
(bendamustine, RIT), improved supportive care measures, and the spective study of 63 cases. J Clin Oncol 29:1445–1451, 2011.
wider implementation of stem cell transplantation. Controversy persists 27. Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follic-
ular lymphoma? Results of a long-term follow-up study of patients treated at Stanford
over whether any of the grades of FL are curable with standard che- University. J Clin Oncol 14:1282–1290, 1996.
moimmunotherapy regimens, although it is clear that OS has improved 28. Friedberg JW, Byrtek M, Link BK, et al: Effectiveness of first-line management strate-
significantly in the last decade. Further clinical research will settle these gies for stage I follicular lymphoma: Analysis of the National LymphoCare Study. J Clin
Oncol 30:3368–3375, 2012.
disputes and permit formulation of a consensus standard of care for the 29. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-
management of both newly diagnosed and relapsed FL. Hodgkin’s lymphomas. N Engl J Med 311:1471–1475, 1984.
30. Ardeshna KM, Smith P, Norton A, et al: Long-term effect of a watch and wait policy
versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin
REFERENCES lymphoma: A randomised controlled trial. Lancet 362:516–522, 2003.
31. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas: Watch-
1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9–29, 2014. ful waiting v aggressive combined modality treatment. Semin Hematol 25:11–16, 1988.
2. Harris NL, Swerdlow SH, Jaffe ES, et al: Follicular lymphoma, in WHO Classification of 32. Brice P, Bastion Y, Lepage E, et al: Comparison in low-tumor-burden follicular lympho-
Tumours of Haematopoietic and Lymphoid Tissues, 4th edition, edited by SH Swerdlow, mas between an initial no-treatment policy, prednimustine, or interferon alfa: A ran-
E Campo, NL Harris, ES Jaffe, SA Pileri, H Stein, J Thiele, JW Vardiman, pp 220–226. domized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude
International Agency for Research on Cancer, Lyon, 2008. des Lymphomes de l’Adulte. J Clin Oncol 15:1110–1117, 1997.
3. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: 33. Friedberg JW, Cohen P, Chen L, et al: Bendamustine in patients with rituximab-re-
First report of the national LymphoCare study. J Clin Oncol 27:1202–1208, 2009. fractory indolent and transformed non-Hodgkin’s lymphoma: Results from a phase II
4. Groves FD, Linet MS, Travis LB, et al: Cancer surveillance series: Non-Hodgkin’s lym- multicenter, single-agent study. J Clin Oncol 26:204–210, 2008.
phoma incidence by histologic subtype in the United States from 1978 through 1995. J 34. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 mono-
Natl Cancer Inst 92:1240–1251, 2000. clonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a
5. Louissaint A Jr, Ackerman AM, Dias-Santagata D, et al: Pediatric-type nodal follicular four-dose treatment program. J Clin Oncol 16:2825–2833, 1998.
lymphoma: An indolent clonal proliferation in children and adults with high prolifera- 35. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as
tion index and no BCL2 rearrangement. Blood 120:2395–2404, 2012. single first-line therapy for patients with follicular lymphoma with a low tumor burden:
6. Liu Q, Salaverria I, Pittaluga S, et al: Follicular lymphomas in children and young Clinical and molecular evaluation. Blood 97:101–106, 2001.
adults: A comparison of the pediatric variant with usual follicular lymphoma. Am 36. Hainsworth JD: Rituximab as first-line systemic therapy for patients with low-grade
J Surg Pathol 37:333–343, 2013. lymphoma. Semin Oncol 27:25–29, 2000.
7. Zelenetz AD, Gordon LI, Wierda WG, et al: Non-Hodgkin’s lymphomas, version 37. Davis TA, Grillo-Lopez AJ, White CA, et al: Rituximab anti-CD20 monoclonal anti-
4.2014. J Natl Compr Canc Netw 12:1282–1303, 2014. body therapy in non-Hodgkin’s lymphoma: Safety and efficacy of re-treatment. J Clin
8. Miller TP, LeBlanc M, Grogan TM, et al: Follicular lymphomas: Do histologic subtypes Oncol 18:3135–3143, 2000.
predict outcome? Hematol Oncol Clin North Am 11:893–900, 1997. 38. Ghielmini M, Schmitz SF, Cogliatti S, et al: Effect of single-agent rituximab given at the stan-
9. Reed JC: Bcl-2-family proteins and hematologic malignancies: History and future dard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of
prospects. Blood 111:3322–3330, 2008. the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23:705–711, 2005.
10. Bouska A, McKeithan TW, Deffenbacher KE, et al: Genome-wide copy-number anal- 39. Hainsworth JD: Rituximab as first-line and maintenance therapy for patients with indo-
yses reveal genomic abnormalities involved in transformation of follicular lymphoma. lent non-Hodgkin’s lymphoma: Interim follow-up of a multicenter phase II trial. Semin
Blood 123:1681–1690, 2014. Oncol 29:25–29, 2002.
11. Hehn ST, Grogan TM, Miller TP: Utility of fine-needle aspiration as a diagnostic tech- 40. Hainsworth JD: First-line and maintenance treatment with rituximab for patients with
nique in lymphoma. J Clin Oncol 22:3046–3052, 2004. indolent non-Hodgkin’s lymphoma. Semin Oncol 30:9–15, 2003.
12. Trotman J, Fournier M, Lamy T, et al: Positron emission tomography-computed tomog- 41. van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical
raphy (PET-CT) after induction therapy is highly predictive of patient outcome in fol- outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with
licular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants. J Clin and without rituximab during induction: Results of a prospective randomized phase 3
Oncol 29:3194–3200, 2011. intergroup trial. Blood 108:3295–3301, 2006.
13. Shipp MA: A predictive model for aggressive non-Hodgkin’s lymphoma. The Inter- 42. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with
national Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329: high tumour burden follicular lymphoma responding to rituximab plus chemotherapy
987–994, 1993. (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42–51, 2011.
14. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic 43. Bachy E, Houot R, Morschhauser F, et al: Long-term follow up of the FL2000 study
index. Blood 104:1258–1265, 2004. comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular
15. Federico M, Bellei M, Pro B: Revalidation of FLIPI in patients with follicular lymphoma lymphoma. Haematologica 98:1107–1114, 2013.
registered in the F2 study and treated upfront with immunochemotherapy. Proc Am Soc 44. Hochster H, Weller E, Gascoyne RD, et al: Maintenance rituximab after cyclophos-
Clin Oncol 25:443s, 2007. phamide, vincristine, and prednisone prolongs progression-free survival in advanced

Kaushansky_chapter 99_p1641-1652.indd 1650 9/18/15 3:57 PM